Impact of metabolic syndrome on prognosis of symptomatic intracranial atherostenosis

Neurology

Volumn 66, Issue 9, 2006, Pages 1344-1349

  Ovbiagele, Bruce ^a,d   Saver, Jeffrey L ^a   Lynn, Michael J ^b   Chimowitz, Marc ^c  

^a UCLA MEDICAL CENTER   (United States)

^b EMORY UNIVERSITY   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; WARFARIN;

ADULT; AGE; AGED; ARTICLE; BRAIN ATHEROSCLEROSIS; CEREBROVASCULAR ACCIDENT; EUROPEAN AMERICAN; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MORTALITY; OCCLUSIVE CEREBROVASCULAR DISEASE; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SEX DIFFERENCE;

AGED; ASPIRIN; BRAIN ISCHEMIA; COHORT STUDIES; COMORBIDITY; CONTINENTAL POPULATION GROUPS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INTRACRANIAL ARTERIOSCLEROSIS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MULTICENTER STUDIES; MYOCARDIAL INFARCTION; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; RISK; RISK FACTORS; SURVIVAL ANALYSIS; VASCULAR DISEASES; WARFARIN;

EID: 33646684547     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000210530.46058.5c     Document Type: Article

References (30)

1. Wilson P. Estimating cardiovascular disease risk and the metabolic syndrome: a Framingham view. Endocrinol Metab Clin North Am 2004;33:467-481, v
2. Report of a WHO consultation. In: Alwan A, King H, eds. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Geneva: World Health Organization, Department of Noncommunicable Disease Surveillance;1999:1-59.
3. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
4. Ford E, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among us adults: findings from the third national health and nutrition examination survey. JAMA 2002;287:356-359.
5. Lakka H, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288:2709-2716.
6. Laaksonen D, Lakka HM, Niskanen LK, et al. Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol 2002;156:1070-1077.
7. Boden-Albala B, Lee HS, Paik MC, et al. Stroke risk and the metabolic syndrome: findings from the Northern Manhattan Stroke Study. Neurology 2003;60:A255.
8. Najarian R, Sullivan LM, Wilson PF, et al. Impact of metabolic syndrome compared to diabetes as a risk factor for stroke: Framingham Offspring Study. Stroke 2004;35:243.
9. Marroquin O, Kip KE, Kelley DE, et al. Metabolic syndrome modifies the cardiovascular risk associated with angiographic coronary artery disease in women: a report from the women's ischemia syndrome evaluation. Circulation 2004;109:714-721.
10. Gorter P, Olijhoek JK, Van Der Graaf Y, et al. Prevalence of the metabolic syndrome in patients with coronary heart disease, cerebrovascular disease, peripheral arterial disease or abdominal aortic aneurysm. Atherosclerosis 2004;173:361-367.
11. Bang O, Kim JW, Lee JH, et al. Association of the metabolic syndrome with intracranial atherosclerotic stroke. Neurology 2005;65:296-298.
12. Design, progress and challenges of a double-blind trial of warfarin versus aspirin for symptomatic intracranial arterial stenosis. Neuroepidemiology 2003;22:106-117.
13. Chimowitz M, Lynn MJ, Hewlett-Smith H, et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 2005;352:1305-1316.
14. American Diabetes Association. Clinical practice recommendations 1997. Diabetes Care 1997;20(suppl 1):S1-S70.
15. Ruland S, Hung E, Richardson D, et al. Impact of obesity and the metabolic syndrome on risk factors in African American stroke survivors: a report from the AAASPS. Arch Neurol 2005;62:386-390.
16. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 2005;112:2735-2752.
17. Collett D, et al. Modeling survival data in medical research. 2nd ed. Boca Raton, FL: Chapman and Hall/CRC, 2003.
18. Baltali M, Gokcel A, Kiziltan HT, et al. Association between the metabolic syndrome and newly diagnosed coronary artery disease. Diabetes Nutr Metab 2003;16:169-175.
19. Kernan W, Inzucchi SE, Viscoli CM, et al. Impaired insulin sensitivity among nondiabetic patients with a recent TIA or ischemic stroke. Neurology 2003;60:1447-1451.
20. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005;28:2289-2304.
21. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-1350.
22. McLaughlin T, Abbasi F, Cheal K, et al. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med 2003;139:802-809.
23. Shadid S, Jensen MD. Effects of pioglitazone versus diet and exercise on metabolic health and fat distribution in upper body obesity. Diabetes Care 2003;26:3148-3152.
24. Satoh N, Ogawa Y, Usui T, et al. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 2003;26:2493-2499.
25. Davidson M. Is treatment of insulin resistance beneficial independent of glycemia? Diabetes Care 2003;26:3184-3186.
26. Insulin Resistance in Stroke (IRIS) Trial. Can be found at http://iristrial.Org/. Last accessed August 12, 2005.
27. International Diabetes Federation. Worldwide definition of the metabolic syndrome. Available at: http://www.Idf.Org/webdata/docs/idf_meta- syndrome_definition.pdf. Accessed September 15, 2005.
28. Einhorn D, Reaven GM, Cobin RH, et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 2003;9:237-252.
29. Ford E, Mokdad AH, Giles WH. Trends in waist circumference among US adults. Obes Res 2003;11:1223-1231.
30. Ferrannini E, Natali A, Bell P, et al. Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR). J Clin Invest 1997;100:1166-1173.